NewLink Genetics to Present at the Credit Suisse 2013 Healthcare Conference
(firmenpresse) - AMES, IA -- (Marketwired) -- 11/06/13 -- NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutics to improve treatment options for patients with cancer, announced today that Charles J. Link, Jr., M.D., NewLink's Founder and Chief Executive Officer, is scheduled to present at the Credit Suisse 2013 Healthcare Conference in Phoenix, Arizona on Tuesday, November 12, 2013 at 5:00 p.m. ET. Interested parties may access a live webcast of the presentation by visiting the NewLink Genetics website at . The webcast will be archived on the NewLink website following the event.
NewLink is a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutic products to improve treatment options for patients with cancer. NewLink's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a wide range of oncology indications. NewLink's product candidates are designed to harness multiple components of the immune system to combat cancer without significant incremental toxicity, either as a monotherapy or in combination with other treatment regimens. For more information please visit . Patient information is available at .
Gordon Link
Chief Financial Officer
515-598-2925
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: Marketwired
Datum: 06.11.2013 - 21:30 Uhr
Sprache: Deutsch
News-ID 313606
Anzahl Zeichen: 0
contact information:
Town:
AMES, IA
Kategorie:
Health & Nutrition
Diese Pressemitteilung wurde bisher 192 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"NewLink Genetics to Present at the Credit Suisse 2013 Healthcare Conference"
steht unter der journalistisch-redaktionellen Verantwortung von
NewLink Genetics Corporation (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).